title: Oligomerization properties of fragile-X mental-retardation protein (FMRP) and the fragile-X-related proteins FXR1P and FXR2P.
abstract: The absence of fragile-X mental-retardation protein (FMRP) results in fragile-X syndrome. Two other fragile-X-related (FXR) proteins have been described, FXR1P and FXR2P, which are both very similar in amino acid sequence to FMRP. Interaction between the three proteins as well as with themselves has been demonstrated. The FXR proteins are believed to play a role in RNA metabolism. To characterize a possible functional role of the interacting proteins the complex formation of the FXR proteins was studied in mammalian cells. Double immunofluorescence analysis in COS cells over-expressing either FMRP ISO12/FXR1P or FMRP ISO12/FXR2P confirmed heterotypic interactions. However, Western-blotting studies on cellular homogenates containing physiological amounts of the three proteins gave different indications. Gel-filtration experiments under physiological as well as EDTA conditions showed that the FXR proteins were in complexes of >600 kDa, as parts of messenger ribonuclear protein (mRNP) particles associated with polyribosomes. Salt treatment shifted FMRP, FXR1P and FXR2P into distinct intermediate complexes, with molecular masses between 200 and 300 kDa. Immunoprecipitations of FMRP as well as FXR1P from the dissociated complexes revealed that the vast majority of the FXR proteins do not form heteromeric complexes. Further analysis by [(35)S]methionine labelling in vivo followed by immunoprecipitation indicated that no proteins other than the FXR proteins were present in these complexes. These results suggest that the FXR proteins form homo-multimers preferentially under physiological conditions in mammalian cells, and might participate in mRNP particles with separate functions.
authors.affiliation: Department of Clinical Genetics and Centre for Biomedical Genetics, Erasmus University, PO Box 1738, 3000 DR Rotterdam, The Netherlands.
authors.forename: F
authors.initials: F
authors.lastname: Tamanini
authors.forename: L
authors.initials: L
authors.lastname: Van Unen
authors.forename: C
authors.initials: C
authors.lastname: Bakker
authors.forename: N
authors.initials: N
authors.lastname: Sacchi
authors.forename: H
authors.initials: H
authors.lastname: Galjaard
authors.forename: B A
authors.initials: BA
authors.lastname: Oostra
authors.forename: A T
authors.initials: AT
authors.lastname: Hoogeveen
mesh_terms: D000818:Animals; D019556:COS Cells; D002850:Chromatography, Gel; D051860:Fragile X Messenger Ribonucleoprotein 1; D005600:Fragile X Syndrome; D006801:Humans; D008607:Intellectual Disability; D008715:Methionine / Q000378:metabolism; D008970:Molecular Weight; D009419:Nerve Tissue Proteins / Q000737:chemistry* / Q000235:genetics / Q000302:isolation & purification; D016601:RNA-Binding Proteins / Q000737:chemistry* / Q000235:genetics / Q000302:isolation & purification; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000302:isolation & purification; D013462:Sulfur Radioisotopes; D014162:Transfection
chemical_list: D051860:Fragile X Messenger Ribonucleoprotein 1; D008715:Methionine; D009419:Nerve Tissue Proteins; D016601:RNA-Binding Proteins; D011994:Recombinant Proteins; D013462:Sulfur Radioisotopes; C497683:FMR1 protein, human; C096916:FXR1 protein, human; C096915:FXR2 protein, human